Press Releases

Printer Friendly Version View printer-friendly version
<< Back
Implant Sciences Announces Over $1,000,000 in New Sales to Customers in Asia
Company reports over $2.2 million in new sales within one week

WILMINGTON, Mass., Dec. 19, 2013 /PRNewswire/ -- Implant Sciences Corporation (OTCQB:IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today it has sold over $1,000,000 worth of its explosives trace detectors (ETD) to numerous customers throughout Asia. The units are to be deployed in a variety of applications such as critical infrastructure protection, aviation security, and VIP protection.

"Our representative office in Shanghai has been highly effective in marketing our products in Asia. We're proud of our team in the region and we believe we have significant additional market penetration and growth opportunities to pursue throughout Asia," stated Vice President of Sales and Marketing for Implant Sciences, Dr. Darryl Jones.

"New sales into China are driven by our systems' well-earned reputation with Chinese customers who have been using them for years. While the demand for our next-generation ETDs remains strong in China, we are also gaining traction in other Asian markets, where more customers are adopting our ETDs," commented Joe Laskey, Implant Sciences' Area Vice President and General Manager, Asian Sales and Business Development.

"With this announcement, Implant Sciences has reported over $2.2 million in new sales this week. We're very pleased with this volume of sales for the month, and we look forward to our sales team extending this momentum in the future," commented Glenn D. Bolduc, Implant Sciences' President and CEO.

About the QS-B220 Desktop Explosives Trace Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About the QS-H150 Handheld Explosives Trace Detector
The QS-H150 utilizes Ion Mobility Spectrometry (IMS) technology, providing fast, accurate detection of trace amounts of a wide variety of military, commercial, and homemade explosives. Built with no radioactive materials and featuring a low-maintenance, self-calibrating, and self-clearing design, the QS-H150 provides very high levels of operational availability. The QS-H150 has been proven to perform well in a wide variety of temperatures and challenging environments, from humid jungles to dry, sand swept deserts.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA qualification for air cargo screening, the Company's QS-B220 has also received STAC certification, a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act), and the GSN 2013 Homeland Security Award for "Best Explosives Detection Solution". For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change, and our success will depend on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact:
Implant Sciences Corporation
Company Contact:
Glenn Bolduc, CEO
978-752-1700

or

Investor Contact:
Laurel Moody
646-810-0608

SOURCE Implant Sciences Corporation

Implant Sciences Corporation, Company Contact: Glenn Bolduc, CEO, 978-752-1700, gbolduc@implantsciences.com, Investor Contact: Laurel Moody, 646-810-0608, lmoody@corporateprofile.com